Elesclomol (STA-4783)

Name: Elesclomol (STA-4783)
Brand: Selleck Chemicals
SKU: S1052
Rating: 5 (10 reviews)

For research use only.

Catalog No.S1052

10 publications

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Selleck's Elesclomol (STA-4783) has been cited by 10 publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275 ( click the link to review the publication )

Nat Commun, 2020, 15;11(1):2423

PubMed: 32415069 ( click the link to review the publication )

EBioMedicine, 2020, 54:102715

PubMed: 32251998 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1645

PubMed: 32575908 ( click the link to review the publication )

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749 ( click the link to review the publication )

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766 ( click the link to review the publication )

BMC Genomics, 2014, 15(1):263

PubMed: 24708151 ( click the link to review the publication )

4 Customer Reviews

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	MnLmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2XVR2lvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh\|ryP	MXzTRW5ITVJ?
CAL-51 cell	M4TYWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NULsUI1DUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF{NjDuUS=>	NI[zdXlUSU6JRWK=
ABC-1 cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1W2V2lvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3PSCwTR?=	MkTyV2FPT0WU
A2780 cell	MmW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{\UfWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6PCCwTR?=	M1XvPXNCVkeHUh?=
ES1 cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M36xZmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD63OFkhdk1?	NVLsbWxSW0GQR1XS
HUTU-80 cell	MlX5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MmLrTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2=	MlXNV2FPT0WU
NCI-H292 cell	NE\GS2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NH;1SYdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0>	MULTRW5ITVJ?
NB69 cell	MoTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEDsVXdKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIzKG6P	MYDTRW5ITVJ?
ES8 cell	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEf3R\|lKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|Ihdk1?	NYTCfW1IW0GQR1XS
BCPAP cell	NYDIfHdiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWjJT2FDUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2=	NUfmPJZUW0GQR1XS
T-24 cell	M3;qZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2HxRmlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVUhdk1?	NIj3dnJUSU6JRWK=
EW-16 cell	M2\pVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62NUBvVQ>?	M4HlWXNCVkeHUh?=
OVCAR-5 cell	NXHaW5A2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnvTTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?=	MmToV2FPT0WU
SF126 cell	M2LHd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MkLDTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVUhdk1?	NEDYVoFUSU6JRWK=
KP-4 cell	NXr1RXlOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWfxbVViUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPyCwTR?=	NF;4THBUSU6JRWK=
GAMG cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4C1XGlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVEhdk1?	NVqzNmdJW0GQR1XS
HOS cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFXx[ZlKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVMhdk1?	M1nRc3NCVkeHUh?=
CHL-1 cell	NWP6UlRST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn3jTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFEhdk1?	MmLnV2FPT0WU
AGS cell	NInWTYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Ml2zTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lki2JI5O	MlWyV2FPT0WU
MDA-MB-157 cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnX2TY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MjDuUS=>	MmrMV2FPT0WU
HSC-3 cell	NVjBTII2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYKyOGx2UW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2=	NEewNWlUSU6JRWK=
CAL-72 cell	NGPl[GdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M{LYcWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	MnSzV2FPT0WU
NBsusSR cell	NUjHR2V6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXntZYxzUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zMzDuUS=>	MkXSV2FPT0WU
ES7 cell	M2XnNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3;6bmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz61PUBvVQ>?	NVLOPHVDW0GQR1XS
H-EMC-SS cell	M1zQTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYnJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?=	MoXmV2FPT0WU
NCI-H1703 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn60TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N	NHLJVVVUSU6JRWK=
BHT-101 cell	MlXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M37rVGlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzJibl2=	M17jW3NCVkeHUh?=
SK-OV-3 cell	Mk\hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXrT[GdkUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=>	M1LXVnNCVkeHUh?=
EW-24 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mm\vTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFMhdk1?	NYjDXXlEW0GQR1XS
PSN1 cell	M3jmbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M2HDTWlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFQhdk1?	Mnm3V2FPT0WU
OVCAR-8 cell	MlXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NWTOT2w6UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy57OTDuUS=>	M1jZOXNCVkeHUh?=
NCI-H1563 cell	NVfBTVQ{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2=	M3rXV3NCVkeHUh?=
SW756 cell	MnLtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xN{BvVQ>?	NWPXcHFrW0GQR1XS
A375 cell	M3XiNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmX4TY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xOEBvVQ>?	NF33OldUSU6JRWK=
Ca9-22 cell	M{Xtc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFPkcoFKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOjVibl2=	NInkOnZUSU6JRWK=
SW1990 cell	NFXDU4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYjWeG1[UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G5PVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjN{IH7N	NEG5bGZUSU6JRWK=
ES4 cell	MnLPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEn1[VRKdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|khdk1?	MW\TRW5ITVJ?
HCE-T cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnK3TY5pcWKrdHnvckBw\iCqdX3hckBJS0VvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOFUhdk1?	NH\DNFFUSU6JRWK=
MOLT-16 cell	NXL4WHBnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlHNTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE42OyCwTR?=	NITkeIxUSU6JRWK=
HSC-4 cell	M4LRNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Ml\FTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuPEBvVQ>?	M3nJSHNCVkeHUh?=
NCI-SNU-1 cell	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1qxZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC56NjDuUS=>	M4POTHNCVkeHUh?=
EW-11 cell	Mn;nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NF7zXpFKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P	Mm\HV2FPT0WU
HT-1080 cell	M3e3WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXPJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P	M37NZ3NCVkeHUh?=
MES-SA/Dx5 cells	MlPjR5l1d3SxeHnjbZR6KGG\|c3H5	NX7XRmRIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{whUUN3ME21JI5O	NInVXVUzOzl\|N{m4NS=>
SW1710 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuNVYhdk1?	M1\uenNCVkeHUh?=
EW-1 cell	NXuzRW5JT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M{ixeGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuNlQhdk1?	MWnTRW5ITVJ?
BV-173 cell	NILOdplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYHNboEyUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7IH7N	M4DQWnNCVkeHUh?=
TE-8 cell	NIjtPJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXXJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkSxJI5O	NYTyVIl3W0GQR1XS
G-401 cell	MmHtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVvJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT60N{BvVQ>?	M2DkVHNCVkeHUh?=
KOSC-2 cell	M2XHeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWOzeppSUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR3IH7N	NUnaWoxWW0GQR1XS
HuCCT1 cell	NVLab3hDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOVIhdk1?	NF2ySGhUSU6JRWK=
FADU cell	NIrsOGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUPjU4JEUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43PiCwTR?=	NVftRnRVW0GQR1XS
MHH-ES-1 cell	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnzuTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjlibl2=	NEPLWHlUSU6JRWK=
ES3 cell	NH;YWGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1TEcGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT63PUBvVQ>?	NYm3b2wzW0GQR1XS
OVCAR-4 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUTDcmpvUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=>	NFfxTIZUSU6JRWK=
HD-MY-Z cell	Ml7US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NX3IdG5KUW6qaXLpeIlwdiCxZjDoeY1idiCKRD3NXU1bKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57MTDuUS=>	NETJdnpUSU6JRWK=
human JAR cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFLwZnpKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVchdk1?	NVHxVIFSW0GQR1XS
A427 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn2xTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj6wO{BvVQ>?	M{S1ZXNCVkeHUh?=
697 cell	M1\NbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3rzfmlvcGmkaYTpc44hd2ZiaIXtZY4hPjl5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj6xN{BvVQ>?	NXHzTmhvW0GQR1XS
OVCAR-3 cell	NFHCOpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVzJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIhdk1?	MmXaV2FPT0WU
human NB14 cell	NXfwZXB2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NHLufo1KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P	NIC3XJRUSU6JRWK=
GB-1 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkS1TY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj63NUBvVQ>?	NUThVGZEW0GQR1XS
COR-L105 cell	NYPOXXdST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Moe2TY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEGwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPzZibl2=	MkfDV2FPT0WU
647-V cell	NUnGO5ZVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NYDEZWJnUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQSCwTR?=	MoXWV2FPT0WU
human K5 cell	M1rIRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXfzXpNxUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUegcm0>	NGrEfGJUSU6JRWK=
DMS-273 cell	NYjzRXZCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P	NYfYWlRDW0GQR1XS
UM-UC-3 cell	MkDjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXnyb3ZSUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=>	NUDtXHo3W0GQR1XS
HEL cell	NIHRdG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEigcm0>	MUXTRW5ITVJ?
human KU-19-19 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVLJcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xQSCwTR?=	MXrTRW5ITVJ?
MC-IXC cell	M1\YW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXTJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuNVchdk1?	MVrTRW5ITVJ?
human H4 cell	M{n1[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NWj2UXhJUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuNlUhdk1?	MnfRV2FPT0WU
NUGC-3 cell	MknWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Ml76TY5pcWKrdHnvckBw\iCqdX3hckBPXUeFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM{KG6P	NF\POoNUSU6JRWK=
CHP-212 cell	NX7PR3hbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYjJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM1KG6P	NYDBPFU5W0GQR1XS
human SW982 cell	NEKw[FFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NE\lVFVKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?=	MoPxV2FPT0WU
C-33-A cell	MoLYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXK2VWlkUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N	M2WwbXNCVkeHUh?=
PC-3 cell	M4HXc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mn20TY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz64PUBvVQ>?	M17lVnNCVkeHUh?=
COLO-684 cell	M1O4N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NXT5V\|BrUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTlwMkGgcm0>	M1rEbXNCVkeHUh?=
SNU-387 cell	M1v6[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEPr[FlKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjR7IH7N	NWPVOXJ{W0GQR1XS
U251 cell	NUn4bIpsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlzrTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;OT64OkBvVQ>?	M3\nfXNCVkeHUh?=
A673 cell	NUj4d\|NET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NF76bldKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P	MWHTRW5ITVJ?
human T47D cell	MnfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NV7WWVNqUW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzlibl2=	NX3yV4E6W0GQR1XS
A549 cell	NV\OSFRjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1jWSGlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUG5MlYhdk1?	NIDDXmxUSU6JRWK=
PC-14 cell	NEfoeWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NEGzWI1KdmirYnn0bY9vKG:oIHj1cYFvKFCFLUG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzNibl2=	MonPV2FPT0WU
A704 cell	M1Xlemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHjI[ItKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{41PSCwTR?=	NF;zSWJUSU6JRWK=
MCF7 cell	MorBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MoTkTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;M{GuN\|Yhdk1?	MnvFV2FPT0WU
PC3 cells	NWLrepE4TnWwY4Tpc44h[XO\|YYm=	MkLWTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN\|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN\|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF\|IN88US=>	MlTMNlE{PDF4N{W=
F-36P cells	MWnQdo9tcW[ncnH0bY9vKGG\|c3H5	NHXjeo9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF[tN\|ZRKGOnbHzzMEBKSzVyPUCuNlgh\|ryP	NF\yXlEzOTN2MU[3OS=>
OCI-AML2 cells	MWLQdo9tcW[ncnH0bY9vKGG\|c3H5	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN\|Uh\|ryP	Mmm4NlE{PDF4N{W=
K562 cells	MUHQdo9tcW[ncnH0bY9vKGG\|c3H5	M1\RdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczygTWM2OD1zODFOwG0>	NI\3bYUzOTN2MU[3OS=>

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

- Collapse

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40%PEG300+5%Tween80 +50%H2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can we use the compound for in vivo mouse studies?
Answer:
S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (HSP90) Signaling Pathway Map

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Features:Displays very low toxicity toward normal cells.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)